Showing 712 results
-
Press release /European Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable…
-
Press release /Oncologic Drugs Advisory Committee (ODAC) votes in favor of recommending biosimilar filgrastim for approval in the US Biosimilar filgrastim recommended to be approved for use in all requested…
-
Press release /Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to…
-
Press release /Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the…
-
Press release /Der Nettoumsatz (0% kWk[2]) bleibt im Gesamtjahr dank starker Performance der Wachstumsprodukte auf Vorjahresniveau Cosentyx (USD 1,1 Milliarden) erreicht Blockbuster-Status Entresto (USD 170…
-
Press release /Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc. to add first-in-class disease modifying topical treatment for presbyopia patients…
-
Press release /Sandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a…
-
Press release /The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig® (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years…
-
Press release /Multicenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84…
-
Press release /The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topics Novartis malaria access plans, widespread registration…